27 October 2008
Analysis of factors interfering with the acceptance of interferon therapy by HCV-infected patients
Yumiko NagaoABDEF, Yutaka KawakamiABE, Tamotsu YoshiyamaC, Michio SataADGMed Sci Monit 2008; 14(11): PI45-52 :: ID: 869425
Abstract
Background
Interferon (IFN) therapy, an antiviral agent, contributes to the prevention of occurrence of hepatocellular carcinoma (HCC) and to improvement in long-term prognosis. However, IFN therapy is not well-implemented in Japan. The present study was conducted to analyze factors preventing the implementation of IFN therapy.
Material and Method
Questionnaires were sent to patients with hepatitis C virus (HCV)-related liver disease who were treated at 7 clinics (by non liver-specialists) and 1 hospital (by liver specialists) and by their attending physicians.
Results
Of 139 patients for whom attending physicians recommended IFN therapy, 92 (66.2%) agreed to receive the treatment. The proportions of patients who agreed to receive IFN therapy were 74 (86.0%) out of 86 hospital patients and 18 (34%) out of 53 clinic patients. In logistic regression analysis, the adjusted odds ratios on treatment facilities, sex and complications were 18.06, 3.65, and 3.63 respectively, indicating that there were significant differences. Female patients more than male patients declined IFN therapy because of worries over the adverse reactions of IFN therapy.
Conclusions
Multivariate analysis showed that factors contributing to the risk that a patient would not consent to receive IFN therapy included a) treatment facilities, b) sex, and c) the presence or absence of complications. It is also essential to devise measures to create cooperation between hospitals and clinics, and to improve communication between physicians and patients.
Keywords: Interferons - therapeutic use, Hepatitis C - pathology, Questionnaires, Aged, 80 and over
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952